You can buy or sell IRWD and other stocks, options, ETFs, and crypto commission-free!
Ironwood Pharmaceuticals, Inc. Class A Common Stock, also called Ironwood Pharmaceuticals, is a commercial biotechnology company, which engages in the discovery, commercialization, and development of medicines. Read More Its products include linaclotide, a guanylate cyclase type-C agonist which treats patients irritable bowel syndrome with constipation and chronic constipation. The company was founded by Peter M. Hecht, Eric F. Summers, G. Todd Milne, Brian M. Cali, Joseph C. Cook Jr., and Gina Bornino Miller in 1998 and is headquartered in Cambridge, MA.
52 Week High
52 Week Low
Yahoo FinanceMar 16
Read This Before Buying Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Shares
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is that there are more than a few examples of insiders dumping stock prior to a period of weak performance. So we’ll take a look at whether insiders have been buying or selling shares in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). What Is Insider Buying? Most investors know that it is quite permissible for company leaders, such as directors of the board, to buy and sell stock on the market. Ho...
Yahoo FinanceMar 15
Why Is Ironwood (IRWD) Down 0.4% Since Last Earnings Report?
Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. A month has gone by since the last earnings report for Ironwood Pharmaceuticals (IRWD). Shares have lost about 0.4% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is Ironwood due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the...
Yahoo FinanceMar 14
Ironwood Announces Effectiveness of Cyclerion Form 10 Registration Statement
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- – “When-issued” trading of CYCN expected to begin on Nasdaq on March 18, 2019 – – Separation completion expected April 1, 2019 – Ironwood Pharmaceuticals, Inc. (IRWD) today announced that the Form 10 Registration Statement filed by Cyclerion Therapeutics, Inc. (Cyclerion) has been declared effective by the U.S. Securities and Exchange Commission (SEC). The Form 10 reflects Ironwood’s plan for a tax-free spin-off of Cyclerion as a publicly-traded company, which is expec...
Expected May 1, Pre-Market